Author

Roger Cady

Observed name: Cady, Roger

Observed institutions: Lundbeck (Denmark), Lundbeck (United States)

OpenAlex ID: A5044974693

Eptinezumab Demonstrated Early and Sustained Reductions in HIT-6 Total and Item Scores Over Time in Patients with Chronic Migraine in the PROMISE-2 Trial (458)

2020 · RJ Wirth, James S. McGinley, et al. · Neurology · 1

Preventive Treatment With Eptinezumab in Patients With a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2 (S47.006)

2023 · Michael J. Marmura, Hans-Christoph Diener, et al. · Neurology

Development and validation of a novel model for characterizing migraine outcomes within electronic health records utilizing artificial intelligence (P8-12.003)

2023 · Steven Kymes, Roger Cady, et al. · Neurology

Patient Preferences for Attributes of Advanced Migraine Prevention Medications: Findings from a Discrete Choice Experiment (P7-12.004)

2023 · Todd J. Schwedt, Ashley Martin, et al. · Neurology

Sécurité cardiovasculaire de l’eptinezumab : analyse poolée des études en double aveugle, randomisées contre placebo

2022 · Timothy Smith, Egilius Spierings, et al. · Revue Neurologique

Works count: 6

Citation count: 1

H-index: 1

I10-index: